Leerink Partnrs Weighs in on Immunome, Inc.’s Q1 2024 Earnings (NASDAQ:IMNM)

Immunome, Inc. (NASDAQ:IMNM) – Equities research analysts at Leerink Partnrs lifted their Q1 2024 earnings per share (EPS) estimates for shares of Immunome in a report issued on Tuesday, March 26th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings of ($1.71) per share for the quarter, up from their previous estimate of ($2.21). Leerink Partnrs has a “Outperform” rating on the stock. The consensus estimate for Immunome’s current full-year earnings is ($0.97) per share. Leerink Partnrs also issued estimates for Immunome’s Q2 2024 earnings at ($0.15) EPS, Q3 2024 earnings at ($0.18) EPS, Q4 2024 earnings at ($0.22) EPS, FY2024 earnings at ($2.17) EPS, FY2025 earnings at ($2.29) EPS and FY2026 earnings at ($2.90) EPS.

Other research analysts also recently issued reports about the company. Wedbush lifted their price target on Immunome from $12.00 to $19.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 23rd. SVB Leerink began coverage on Immunome in a research report on Monday, January 29th. They issued an “outperform” rating and a $30.00 price target on the stock. Five analysts have rated the stock with a buy rating, According to MarketBeat, Immunome currently has an average rating of “Buy” and a consensus target price of $24.50.

Immunome Stock Performance

IMNM opened at $24.68 on Friday. The business has a 50 day moving average price of $22.31 and a 200 day moving average price of $13.48. Immunome has a twelve month low of $4.44 and a twelve month high of $30.96.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in shares of Immunome by 339.0% during the fourth quarter. Vanguard Group Inc. now owns 1,740,026 shares of the company’s stock valued at $18,618,000 after purchasing an additional 1,343,697 shares during the period. Avidity Partners Management LP bought a new stake in shares of Immunome during the fourth quarter valued at approximately $14,268,000. Price T Rowe Associates Inc. MD increased its position in shares of Immunome by 505.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,051,222 shares of the company’s stock valued at $11,249,000 after purchasing an additional 877,592 shares during the period. Point72 Asset Management L.P. increased its position in shares of Immunome by 25.0% during the fourth quarter. Point72 Asset Management L.P. now owns 682,619 shares of the company’s stock valued at $7,304,000 after purchasing an additional 136,700 shares during the period. Finally, TD Asset Management Inc bought a new stake in shares of Immunome during the third quarter valued at approximately $1,063,000. 44.58% of the stock is owned by institutional investors.

Immunome Company Profile

Immunome, Inc operates as a biotechnology company that develops targeted cancer therapies. Its portfolio includes immunotherapies, targeted effectors, radioligand therapies, and antibody drug conjugates (ADCs). The company also offers rapid screening of novel antibodies and targets through memory B cell hybridoma technology.